Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug;72(8):e31814.
doi: 10.1002/pbc.31814. Epub 2025 May 19.

Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series

Michael R Sargen  1 , Madeline H Fitzhugh  2 , Jennifer S Ko  3 , Allison G Close  4 , Sara C Horton  5 , Faizan Malik  6 , Larissa V Furtado  6 , Armita Bahrami  7 , Brittani K N Seynnaeve  8 , Alberto S Pappo  9 , Vincent Liu  2 , Kevin Cheung  2 , Svetlana D Pack  10 , Liqiang Xi  10 , Mark Raffeld  10 , Ina Lee  10 , Jeffrey Gagan  10 , Kenneth Aldape  10 , Frederic G Barr  10 , Stephen M Hewitt  10 , Christina K Ferrone  10 , Anna Hayden  11 , Jessica N Hatton  1 , Alisa M Goldstein  1 , Ruth M Pfeiffer  1 , Brigitte Widemann  12 , Mary Frances Wedekind Malone  12 , Andrea M Gross  12 , Rosandra Kaplan  12 , Marielle E Yohe  13 , Kristen G Berrebi  2
Affiliations
Case Reports

Clinicopathologic Features, Management, and Outcomes Of Pediatric CRTC1::TRIM11 and MED15::ATF1 Tumors With Spitzoid Morphology: A Case Series

Michael R Sargen et al. Pediatr Blood Cancer. 2025 Aug.

Abstract

Limited information is available on the clinicopathologic features and management of pediatric CRTC1::TRIM11 (CTRTs) and MED15::ATF1-rearranged tumors (MARTs). In this series of pediatric CTRTs (n = 5) and MARTs (n = 2), all tumors exhibited spitzoid morphology and expressed melanocytic markers. Metastatic progression occurred in one CTRT and two MARTs: all three received immunotherapy, resulting in disease control in two patients and one death due to progressive disease. A fourth individual had lymph node micrometastasis that remained stable without progression. This case series highlights the potentially aggressive behavior of these tumors and suggests that immunotherapy may be an effective treatment option for advanced disease.

Keywords: CRTC1::TRIM11 fusion; MED15::ATF1 fusion; Spitz; immunotherapy; melanoma; spitzoid.

PubMed Disclaimer

References

    1. D. E. Elder, B. C. Bastian, I. A. Cree, D. Massi, and R. A. Scolyer, “The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway,” Archives of Pathology & Laboratory Medicine 144, no. 4 (2020): 500–522.
    1. M. R. Sargen, R. L. Barnhill, D. E. Elder, et al., “Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non‐Spitz Melanocytic Tumors (Melanocytomas): A Report from Children's Oncology Group,” Journal of Clinical Oncology 43, no. 9 (2025): 1157–1167.
    1. S. Lee, R. L. Barnhill, R. Dummer, et al., “TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients With Spitzoid Melanocytic Neoplasms,” Scientific Reports 5 (2015): 11200.
    1. B. E. Vest, C. L. Harview, V. Liu, et al., “Cutaneous Melanocytic Tumor With CRTC1::TRIM11 Fusion and Prominent Epidermal Involvement: A Case Report,” Journal of Cutaneous Pathology 49, no. 12 (2022): 1025–1030.
    1. B. E. Vest, K. G. Berrebi, M. S. Stone, M. R. Sargen, and P. Gerami, “CRTC1::TRIM11 cutaneous Tumor: An Update With Local Recurrence and Lung Metastasis in a Pediatric Patient,” Journal of Cutaneous Pathology 51, no. 3 (2024): 181–183.

Publication types

LinkOut - more resources